Pfizer Inc. Files 8-K: Financial Update
Ticker: PFE · Form: 8-K · Filed: Jul 30, 2024 · CIK: 78003
| Field | Detail |
|---|---|
| Company | Pfizer Inc (PFE) |
| Form Type | 8-K |
| Filed Date | Jul 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.05 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, sec-filing
Related Tickers: PFE
TL;DR
Pfizer dropped its 8-K on July 30th, check the financials.
AI Summary
On July 30, 2024, Pfizer Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and exhibits, indicating ongoing financial reporting and disclosure activities for the pharmaceutical giant.
Why It Matters
This filing provides stakeholders with crucial updates on Pfizer's financial performance and operational status, essential for investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any unusual or immediate risks.
Key Players & Entities
- Pfizer Inc. (company) — Registrant
- July 30, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 13-5315170 (identification_number) — I.R.S. Employer Identification No.
- 66 Hudson Boulevard East (address) — Principal executive offices
- New York, New York (address) — Principal executive offices
- 10001-2192 (zip_code) — Principal executive offices
- ( 212 ) 733-2323 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Pfizer Inc.?
The primary purpose of this 8-K filing is to report on Pfizer Inc.'s Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on July 30, 2024.
In which U.S. state is Pfizer Inc. incorporated?
Pfizer Inc. is incorporated in Delaware.
What is Pfizer Inc.'s principal executive office address?
Pfizer Inc.'s principal executive office is located at 66 Hudson Boulevard East, New York, New York, 10001-2192.
What is the IRS Employer Identification Number for Pfizer Inc.?
Pfizer Inc.'s IRS Employer Identification Number is 13-5315170.
Filing Stats: 608 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-07-30 08:04:27
Key Financial Figures
- $0.05 — ange on which registered Common Stock, $0.05 par value PFE New York Stock Exchange
Filing Documents
- pfe-20240730.htm (8-K) — 34KB
- pfe-6302024xex99.htm (EX-99) — 916KB
- pfizerlogo.jpg (GRAPHIC) — 38KB
- 0000078003-24-000155.txt ( ) — 1225KB
- pfe-20240730.xsd (EX-101.SCH) — 3KB
- pfe-20240730_def.xml (EX-101.DEF) — 15KB
- pfe-20240730_lab.xml (EX-101.LAB) — 27KB
- pfe-20240730_pre.xml (EX-101.PRE) — 16KB
- pfe-20240730_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On July 30, 2024, Pfizer Inc. ("Pfizer") issued a press release announcing its financial results for the second quarter of 2024. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein. The information furnished pursuant to this "Item 2.02 - Results of Operations and Financial Condition", including Exhibit 99, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Exhibit Description Exhibit 99 Press Release of Pfizer Inc. dated July 30, 2024 , reporting Pfizer's financial results for the second quarter of 2024. 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. EXHIBIT INDEX Exhibit No. Description 99 Press Release of Pfizer Inc. dated July 30, 2024, reporting Pfizer's financial results for the second quarter of 2024. 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PFIZER INC. By: /s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel Dated: July 30, 2024